Published in Hepatitis Weekly, June 14th, 2004
Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the hepatitis C virus (HCV), the most common blood-borne infection in the U.S.A. Benitec anticipates a ddRNAi- based therapeutic for HCV will enter the clinic in 2005. Under the terms of the agreement, Benitec will issue 7.6m shares to Avocel, representing approximately 9% of the enlarged share capital of Benitec, Ltd.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.